Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Systematic localization of common disease-associated variation in regulatory DNA.
Association Between CD24-P226-C/T Polymorphism and Multiple Sclerosis: A Meta-Analysis.
Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab.
Do cortical lesions help us to distinguish MS from NMO?
Purinergic receptor P2RY12-dependent microglial closure of the injured blood-brain barrier.
Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.
Where Do AQP4 Antibodies Fit in the Pathogenesis of NMO?
Extracting quantitative measures from EAP: a small clinical study using BFOR.
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
Epstein-Barr virus cause of multiple sclerosis.
Exosomes as a potential novel therapeutic tools against neurodegenerative diseases.
Use of Neurofeedback to Enhance Response to Hypnotic Analgesia in Individuals With Multiple Sclerosis.
Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes.
Genotype-phenotype correlation for non-HLA disease associated risk alleles in multiple sclerosis.
Neuroprotection With Phenytoin in Optic Neuritis
Atypical forms of optic neuritis.
The invisible gorilla strikes again: sustained inattentional blindness in expert observers.
Future clinical challenges in multiple sclerosis: Relevance to sphingosine 1-phosphate receptor modulator therapy.
Signaling and Regulatory Functions of Bioactive Sphingolipids as Therapeutic Targets in Multiple Sclerosis.
Pathogenic features of CD4(+)CD28(-) T cells in immune disorders.
Levofloxacin-Induced Delirium in a Patient Suffering from Schizoaffective Disorder and Multiple Sclerosis.
Hematologic modifications in natalizumab-treated multiple sclerosis patients: An 18-month longitudinal study.
The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury.
Alemtuzumab: The advantages and challenges of a novel therapy in MS.
Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients.

Pages